Cita APA (7a ed.)

D, M., D, C., B, C., P, K., & TC, B. (2021). A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease. Dove Medical Press.

Cita Chicago Style (17a ed.)

D, McMullin, Clark D, Cavanagh B, Karpecki P, y Brady TC. A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease. Dove Medical Press, 2021.

Cita MLA (8a ed.)

D, McMullin, et al. A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease. Dove Medical Press, 2021.